Access count of this item: 649

Files in This Item:
File Description SizeFormat 
33_1728.pdf262.28 kBAdobe PDFView/Open
Title: 膀胱癌, 腎細胞癌に対するUFTの使用経験
Other Titles: Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma
Authors: 中神, 義三  KAKEN_name
林, 昭棟  KAKEN_name
伊藤, 博  KAKEN_name
平沢, 精一  KAKEN_name
淡輪, 邦男  KAKEN_name
藤岡, 良彰  KAKEN_name
小川, 秀弥  KAKEN_name
田中, 求平  KAKEN_name
山田, 記道  KAKEN_name
石井, 洋二  KAKEN_name
引間, 規夫  KAKEN_name
Author's alias: Nakagami, Yoshizo
Lin, Tsaw Tung
Ito, Hiroshi
Hirasawa, Seiichi
Tannawa, Kunio
Fujioka, Yoshiaki
Ogawa, Hideya
Tanaka, Kyuhei
Yamada, Norimichi
Ishii, Yoji
Hikima, Norio
Keywords: Adult
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carcinoma, Renal Cell/drug therapy
Carcinoma, Transitional Cell/drug therapy
Kidney Neoplasms/drug therapy
Middle Aged
Tegafur/administration & dosage
Uracil/administration & dosage
Urinary Bladder Neoplasms/drug therapy
Issue Date: Oct-1987
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 33
Issue: 10
Start page: 1728
End page: 1732
Abstract: The safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma. Daily doses of UFT were 300-600 mg, and average total doses administered were 102.0 g for bladder cancer and 116.6 g for renal cell carcinoma cases. Incidence of adverse effects were 25.0% in bladder cancer and 18.5% in renal cell carcinoma cases. Anorexia, nausea, vomiting and decrease in WBC were observed, but rates of having discontinued the administration of UFT were very low, being 9.1% in bladder cancer and 10.0% in renal cell carcinoma. Thus, UFT was considered to be tolerable during prolonged use in bladder cancer and renal cell carcinoma and also a drug in which more usefulness is expected in multidisciplinary treatments in future.
PubMed ID: 3128071
Appears in Collections:Vol.33 No.10

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.